(PDF) Highly Selective Inhibition of Tyrosine Kinase 2

Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165

doi 10.1021/acs.jmedchem.9b00444.s001

Full Text

Abstract

Available in full text

Date

Unknown

Authors

Unknown

Publisher

American Chemical Society (ACS)

Related search

Inhibition of IgE-mediated Secretion From Human Basophils With a Highly Selective Bruton's Tyrosine Kinase, Btk, Inhibitor

International Immunopharmacology

English

Discovery of Zanubrutinib (BGB-3111), a Novel, Potent and Selective Covalent Inhibitor of Brutons Tyrosine Kinase

English

Inhibition of Angiogenesis by Erbstatin, an Inhibitor of Tyrosine Kinase.

Journal of Antibiotics

English

Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable Γ-Secretase Inhibitor

ACS Medicinal Chemistry Letters

Organic Chemistry

English

Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor

Journal of Clinical Pharmacology

English

B Cell Lymphoma 2 (BCL-2; BCL2); Tyrosine Kinase 2 (TYK2); Signal Transducer and Activator of Transcription 1 (STAT1)

Science-Business eXchange

English

Discovery and Preclinical Evaluation of BMS-955829 a Potent Positive Allosteric Modulator of mGluR5

English

Targeting Treg Signaling for the Treatment of Autoimmune Diseases

Current Opinion in Immunology

English

The Use of Stem Cells for the Treatment of Autoimmune Diseases

Brazilian Journal of Medical and Biological Research

English